Cantata Bio

Executive Summary

Cantata Bio, operating under the Dovetail Genomics brand, is a San Diego-based biotechnology company specializing in linked-read genomic solutions. Its proprietary platform captures long-range genomic information, enabling high-resolution genome assembly, 3D chromatin mapping, and comprehensive variant detection. The company serves researchers in oncology, evolutionary biology, and epigenetics through kits, services, and bioinformatics tools. Founded in 2013, Cantata Bio occupies a niche in the genomics tools market, differentiating itself by providing long-range context without the high cost or complexity of long-read sequencing. Its technology is particularly valuable for applications requiring phased genomes, structural variant detection, and chromatin conformation analysis. The company likely operates with a lean structure, focusing on academic and commercial research partnerships. While specific financial details are undisclosed, the firm has maintained a steady presence in the genomics field, suggesting a sustainable business model supported by recurring kit sales and service contracts.

Upcoming Catalysts (preview)

• Q3 2026Launch of an updated or next-generation linked-read sequencing kit with improved throughput or lower cost70% success
• Q3 2026Announcement of a strategic partnership with a major pharmaceutical company for cancer genomics applications50% success
• TBDPeer-reviewed publication demonstrating new utility of its chromatin mapping technology in a high-impact journal80% success